Aquestive Therapeutics Shares Rise, FDA Forgos Meeting on Anaphylm

Dow Jones

09/05

By Dean Seal

Shares of Aquestive Therapeutics climbed after the company said federal regulators wouldn't require an advisory committee meeting for its anaphylaxis treatment Anaphylm.

The stock was up 20% at $4.74 on Thursday. Shares have gained 33% since the start of the year.

The Food and Drug Administration has informed Aquestive that an advisory committee meeting, which tends to slow the agency's approval process, wouldn't be required for Anaphylm to get approved, the pharmaceutical company said.

Aquestive's new drug application for Anaphylm remains on track for an FDA approval target date of Jan. 31, the company said.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

September 04, 2025 12:17 ET (16:17 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2565098863"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565098863\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565098863?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-05 00:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565098863","market":"sg","top_or_hot":-1,"title":"Aquestive Therapeutics Shares Rise, FDA Forgos Meeting on Anaphylm","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Aquestive <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> climbed after the company said federal regulators wouldn't require an advisory committee meeting for its anaphylaxis treatment Anaphylm. \n</p>\n<p>\n  The stock was up 20% at $4.74 on Thursday. Shares have gained 33% since the start of the year. \n</p>\n<p>\n  The Food and Drug Administration has informed Aquestive that an advisory committee meeting, which tends to slow the agency's approval process, wouldn't be required for Anaphylm to get approved, the pharmaceutical company said. \n</p>\n<p>\n  Aquestive's new drug application for Anaphylm remains on track for an FDA approval target date of Jan. 31, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 04, 2025 12:17 ET (16:17 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aquestive Therapeutics Shares Rise, FDA Forgos Meeting on Anaphylm</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAquestive Therapeutics Shares Rise, FDA Forgos Meeting on Anaphylm\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-09-05 00:17</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Aquestive <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> climbed after the company said federal regulators wouldn't require an advisory committee meeting for its anaphylaxis treatment Anaphylm. \n</p>\n<p>\n  The stock was up 20% at $4.74 on Thursday. Shares have gained 33% since the start of the year. \n</p>\n<p>\n  The Food and Drug Administration has informed Aquestive that an advisory committee meeting, which tends to slow the agency's approval process, wouldn't be required for Anaphylm to get approved, the pharmaceutical company said. \n</p>\n<p>\n  Aquestive's new drug application for Anaphylm remains on track for an FDA approval target date of Jan. 31, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 04, 2025 12:17 ET (16:17 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2565098863","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565098863","pubTimestamp":1757002620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Aquestive Therapeutics climbed after the company said federal regulators wouldn't require an advisory committee meeting for its anaphylaxis treatment Anaphylm.The stock was up 20% at $4.74 on Thursday. Shares have gained 33% since the start of the year.The Food and Drug Administration has informed Aquestive that an advisory committee meeting, which tends to slow the agency's approval process, wouldn't be required for Anaphylm to get approved, the pharmaceutical company said.Aquestive's new drug application for Anaphylm remains on track for an FDA approval target date of Jan. 31, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","AQST":"Aquestive Therapeutics Inc.","BK4007":"制药","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"Aquestive Therapeutics股价上涨，FDA取消就过敏问题召开会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AQST":0.9,"LENZ":1},"content_text":"By Dean Seal \n\n\n \n\n\n  Shares of Aquestive Therapeutics climbed after the company said federal regulators wouldn't require an advisory committee meeting for its anaphylaxis treatment Anaphylm. \n\n\n  The stock was up 20% at $4.74 on Thursday. Shares have gained 33% since the start of the year. \n\n\n  The Food and Drug Administration has informed Aquestive that an advisory committee meeting, which tends to slow the agency's approval process, wouldn't be required for Anaphylm to get approved, the pharmaceutical company said. \n\n\n  Aquestive's new drug application for Anaphylm remains on track for an FDA approval target date of Jan. 31, the company said. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 04, 2025 12:17 ET (16:17 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}